NO883456D0 - Bioforenlige, stabile og konsentrerte fluorcarbonemulsjoner for kontrastoekning og oxygentransport invortes i dyr. - Google Patents

Bioforenlige, stabile og konsentrerte fluorcarbonemulsjoner for kontrastoekning og oxygentransport invortes i dyr.

Info

Publication number
NO883456D0
NO883456D0 NO883456A NO883456A NO883456D0 NO 883456 D0 NO883456 D0 NO 883456D0 NO 883456 A NO883456 A NO 883456A NO 883456 A NO883456 A NO 883456A NO 883456 D0 NO883456 D0 NO 883456D0
Authority
NO
Norway
Prior art keywords
emulsion
fluorocarbon
reduces
osmotic
buffering agents
Prior art date
Application number
NO883456A
Other languages
English (en)
Other versions
NO883456L (no
NO179162B (no
NO179162C (no
Inventor
David M Long Jr
Original Assignee
David M Long Jr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David M Long Jr filed Critical David M Long Jr
Publication of NO883456D0 publication Critical patent/NO883456D0/no
Publication of NO883456L publication Critical patent/NO883456L/no
Publication of NO179162B publication Critical patent/NO179162B/no
Publication of NO179162C publication Critical patent/NO179162C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/734—Fullerenes, i.e. graphene-based structures, such as nanohorns, nanococoons, nanoscrolls or fullerene-like structures, e.g. WS2 or MoS2 chalcogenide nanotubes, planar C3N4, etc.
    • Y10S977/735—Carbon buckyball
    • Y10S977/737—Carbon buckyball having a modified surface
    • Y10S977/738—Modified with biological, organic, or hydrocarbon material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/895—Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Carbon And Carbon Compounds (AREA)
NO883456A 1987-08-05 1988-08-04 Biokompatible, stabile og konsentrerte fluorcarbonemulsjoner, fremgangsmåte for fremstilling av slike samt anvendelse ved fremstilling av et administreringssystem NO179162C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/082,846 US4987154A (en) 1986-01-14 1987-08-05 Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use

Publications (4)

Publication Number Publication Date
NO883456D0 true NO883456D0 (no) 1988-08-04
NO883456L NO883456L (no) 1989-02-06
NO179162B NO179162B (no) 1996-05-13
NO179162C NO179162C (no) 1996-08-21

Family

ID=22173820

Family Applications (1)

Application Number Title Priority Date Filing Date
NO883456A NO179162C (no) 1987-08-05 1988-08-04 Biokompatible, stabile og konsentrerte fluorcarbonemulsjoner, fremgangsmåte for fremstilling av slike samt anvendelse ved fremstilling av et administreringssystem

Country Status (9)

Country Link
US (1) US4987154A (no)
EP (1) EP0307087B1 (no)
AT (1) ATE106722T1 (no)
CA (1) CA1316820C (no)
DE (1) DE3850012T2 (no)
ES (1) ES2056932T3 (no)
IE (1) IE64245B1 (no)
NO (1) NO179162C (no)
ZA (1) ZA885796B (no)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5847009A (en) 1986-01-14 1998-12-08 Alliance Pharmaceutical Corp. Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions
US5284645A (en) * 1987-08-05 1994-02-08 Alliance Pharmaceutical Corp. Fluorocarbon emulsions containing amino acid based anti-inflamatory agents and buffer systems
US5219538A (en) * 1987-03-13 1993-06-15 Micro-Pak, Inc. Gas and oxygen carrying lipid vesicles
US6022849A (en) * 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
US6204009B1 (en) 1988-05-16 2001-03-20 BAXTER BIOTECH TECHNOLOGY SàRL Nucleic acids encoding mutant recombinant hemoglobins containing heme pocket mutations
US4951673A (en) * 1988-08-19 1990-08-28 Alliance Pharmaceutical Corp. Magnetic resonance imaging with perfluorocarbon hydrides
JPH0372423A (ja) * 1989-05-26 1991-03-27 Green Cross Corp:The パーフルオロカーボン化合物含有乳化製剤
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6146657A (en) * 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US20020150539A1 (en) * 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5922304A (en) * 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6001335A (en) * 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5196199A (en) * 1990-12-14 1993-03-23 Fuisz Technologies Ltd. Hydrophilic form of perfluoro compounds and method of manufacture
US5874062A (en) * 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
FR2679150A1 (fr) * 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
MX9205298A (es) * 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
US6723303B1 (en) 1991-09-17 2004-04-20 Amersham Health, As Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
JP3231768B2 (ja) * 1991-09-17 2001-11-26 ソーナス ファーマシューティカルス，インコーポレイテッド 気体状超音波造影剤及び超音波造影剤として使用する気体の選定方法
US5264220A (en) * 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
US5344393A (en) * 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US5350359A (en) * 1992-07-16 1994-09-27 Temple University Of The Commonwealth System Of Higher Education Control, treatment and/or diagnosis of physiological conditions with degassed perfluorocarbon liquid
US5628930A (en) * 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
US5595687A (en) * 1992-10-30 1997-01-21 Thomas Jefferson University Emulsion stability
IL108416A (en) 1993-01-25 1998-10-30 Sonus Pharma Inc Colloids with phase difference as contrast ultrasound agents
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
PL176116B1 (pl) * 1993-01-25 1999-04-30 Sonus Pharma Inc Środek kontrastowy do ultrasonografii i sposób wytwarzania środka kontrastowego do ultrasonografii
FR2700696B1 (fr) * 1993-01-28 1995-04-07 Atta Dispersions, émulsions, microémulsions, gels et compositions à usage biomédical comprenant un composé organique fluoré iodé, utilisables notamment comme agent de contraste.
US5635538A (en) * 1993-03-16 1997-06-03 Alliance Pharmaceutical Corp. Fluorocarbon emulsions with reduced pulmonary gas-trapping properties
WO1994021303A1 (en) * 1993-03-16 1994-09-29 Alliance Pharmaceutical Corp. Fluorocarbon compositions containing a visible or fluorescent label
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5470885A (en) * 1993-09-29 1995-11-28 The Research Foundation Of The State University Of New York Fluorocarbons as anti-inflammatory agents
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5658962A (en) 1994-05-20 1997-08-19 Minnesota Mining And Manufacturing Company Omega-hydrofluoroalkyl ethers, precursor carboxylic acids and derivatives thereof, and their preparation and application
US5502094A (en) * 1994-05-20 1996-03-26 Minnesota Mining And Manufacturing Company Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
US5736121A (en) * 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
FR2720943B1 (fr) * 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
RU2088223C1 (ru) * 1994-06-29 1997-08-27 Игорь Вячеславович Белов Антиметастатическое средство
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5997898A (en) * 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US5726209A (en) * 1995-06-07 1998-03-10 Alliance Pharmaceutical Corp. Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US5741248A (en) * 1995-06-07 1998-04-21 Temple University-Of The Commonwealth System Of Higher Education Fluorochemical liquid augmented cryosurgery
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US5667809A (en) * 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5865784A (en) * 1995-06-07 1999-02-02 Alliance Pharmaceutical Corp. Method of hemodilution facilitated by monitoring oxygenation status
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5611344A (en) * 1996-03-05 1997-03-18 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
PT904113E (pt) * 1996-03-05 2004-09-30 Acusphere Inc Gases fluorados microencapsulados para utilizacao como agentes de aquisicao de imagem
US5861175A (en) 1996-03-15 1999-01-19 Alliance Pharmaceutical Corp. Use of fluorocarbons for diagnosis and treatment of articular disorders
EP0935415B1 (en) * 1996-05-01 2006-11-22 Imarx Pharmaceutical Corp. In vitro methods for delivering nucleic acids into a cell
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
EP0977597B1 (en) * 1996-09-11 2003-01-15 Imarx Pharmaceutical Corp. Improved methods for diagnostic imaging using a contrast agent and a vasodilator
US5814601A (en) * 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
DE69831248T2 (de) * 1997-02-28 2006-04-13 The Regents Of The University Of California, Oakland Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US20050019266A1 (en) * 1997-05-06 2005-01-27 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
DE19721947C2 (de) * 1997-05-21 1999-04-22 Diagnostikforschung Inst Verwendung von pharmazeutischen Zubereitungen, die Partikel, Vesikel oder Polymere sowie nichtsteroidale Antirheumatika und/oder Thrombozytenaggregationshemmer zur Darstellung der Gefäße, Lymphknoten und des Knochenmarks enthalten
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US6127430A (en) * 1998-12-16 2000-10-03 3M Innovative Properties Company Microemulsions containing water and hydrofluroethers
US6159917A (en) * 1998-12-16 2000-12-12 3M Innovative Properties Company Dry cleaning compositions containing hydrofluoroether
RU2161122C1 (ru) * 1999-09-10 2000-12-27 Институт молекулярной генетики РАН Способ ускорения окисления оксида азота (no) в гетерогенной среде
AU2000279747A1 (en) 2000-07-20 2002-02-05 Otkrytoe Aktsionernoe Obschestvo Nauchno-Proizvodstvennaya Firma "Perftoran" Emulsion of perfluororganic compounds for medical purposes, method for producingsaid emulsion and methods for curing and preventing diseases with the aid of the emulsion
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
ES2305368T3 (es) * 2002-05-10 2008-11-01 THE PROCTER & GAMBLE COMPANY Tisu estampado en relieve que tiene fibras superficiales sueltas y metodo para su produccion.
JP3912206B2 (ja) * 2002-07-05 2007-05-09 株式会社日立製作所 筒内直接燃料噴射装置用燃料ポンプ
US7682603B2 (en) * 2003-07-25 2010-03-23 The Trustees Of The University Of Pennsylvania Polymersomes incorporating highly emissive probes
US20050151112A1 (en) * 2004-01-14 2005-07-14 Minor Barbara H. 1,1,1,2,2,3,3,4,4-Nonafluoro-4-methoxybutane refrigerant compositions comprising hydrofluorocarbon, and uses thereof
ES2491891T3 (es) 2004-01-16 2014-09-08 Carnegie Mellon University Marcaje celular para técnicas de resonancia magnética nuclear
US7534221B2 (en) 2004-05-24 2009-05-19 The Trustees Of Columbia University In The City Of New York Devices and methods for protecting against distal embolisms
US8012457B2 (en) * 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
CN100574811C (zh) * 2005-01-10 2009-12-30 重庆海扶(Hifu)技术有限公司 一种高强度聚焦超声治疗用微粒类助剂及其应用
CN100574809C (zh) * 2005-01-10 2009-12-30 重庆海扶(Hifu)技术有限公司 一种高强度聚焦超声治疗用氟碳乳剂类助剂及其应用
CN100427142C (zh) * 2005-01-10 2008-10-22 重庆海扶(Hifu)技术有限公司 一种高强度聚焦超声治疗用助剂及其筛选方法
EP2010646A2 (en) 2006-04-14 2009-01-07 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
JP5645658B2 (ja) 2007-07-10 2014-12-24 カーネギー メロン ユニバーシティー 核磁気共鳴技術のための細胞標識を製造するための組成物及び方法
WO2012003457A1 (en) * 2010-07-01 2012-01-05 Mtm Research Llc Anti-fibroblastic fluorochemical emulsion therapies
GB2482911A (en) * 2010-08-20 2012-02-22 Sphere Fluidics Ltd Microdroplet emulsion system
DE102012100859B4 (de) 2012-02-02 2015-12-17 Rwth Aachen Verfahren zum Herstellen dreidimensionaler Strukturen und solche Strukturen
US10881735B2 (en) 2015-11-20 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Phase change nanodroplet conjugates for targeted delivery
US20190201556A1 (en) 2016-05-16 2019-07-04 Mtm Research, Llc Fluorochemical targeted therapies
JP6889535B2 (ja) * 2016-10-05 2021-06-18 デンカ株式会社 赤血球の凝集方法及び分離方法並びに赤血球凝集用試薬

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH604490A5 (no) * 1970-09-05 1978-09-15 Green Cross Corp
US3958014A (en) * 1970-09-05 1976-05-18 The Green Cross Corporation Process for preparing injection-purpose fluorocarbon emulsion capable of carrying oxygen
US3818229A (en) * 1970-12-21 1974-06-18 Univ Illinois Radiopaque agents comprising brominated perfluorocarbons
US3975512A (en) * 1970-12-21 1976-08-17 University Of Illinois Foundation Non-toxic brominated perfluorocarbons radiopaque agents
JPS5331209B2 (no) * 1973-10-05 1978-09-01
US4073879A (en) * 1974-08-26 1978-02-14 University Of Illinois Foundation Brominated perfluorocarbon radiopaque agents
US4105798A (en) * 1976-07-19 1978-08-08 Sun Ventures, Inc. Perfluoro polycyclic compounds for use as synthetic blood and perfusion media
US4146499A (en) * 1976-09-18 1979-03-27 Rosano Henri L Method for preparing microemulsions
JPS5658032A (en) * 1979-10-09 1981-05-20 Tsudakoma Ind Co Ltd Weft yarn storage apparatus of shuttle less loom
JPS5616314A (en) * 1979-07-20 1981-02-17 Fujitsu Ltd Surface elastic wave filter
JPS5759067A (en) * 1980-09-24 1982-04-09 Mazda Motor Corp Energizing device for glow plug of diesel engine
JPS5759046A (en) * 1980-09-29 1982-04-09 Nissan Motor Co Ltd Air fuel ratio control device
US4343797A (en) * 1981-01-05 1982-08-10 Ecanow Charles S Synthetic whole blood and a method of making the same
US4439424A (en) * 1981-01-05 1984-03-27 Neomed Inc. Synthetic whole blood
JPS5896061A (ja) * 1981-11-30 1983-06-07 Green Cross Corp:The パ−フルオロ環状アミン
US4451251A (en) * 1982-03-03 1984-05-29 Thomas Jefferson University Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
FR2523956A1 (fr) * 1982-03-26 1983-09-30 Ugine Kuhlmann Bis-(perfluoroalkyl)-1,2-ethenes ramifies, leur preparation et leur utilisation comme transporteurs d'oxygene convertisseur electromecanique
US4397870A (en) * 1982-07-27 1983-08-09 The University Of Pennsylvania Process for prolonging retention of emulsion particles in the bloodstream
US4497829A (en) * 1982-07-27 1985-02-05 The University Of Pennsylvania Process for preparing perfluorochemical emulsion artificial blood
US4423077A (en) * 1982-07-27 1983-12-27 The University Of Pennsylvania Perfluorochemical emulsion artificial blood
EP0103358B1 (en) * 1982-08-07 1986-10-08 Green Cross Corporation Perfluoro-1-azatricyclic amine compound
JPS5960166A (ja) * 1982-09-27 1984-04-06 三菱電機株式会社 凍結装置
JPS5967229A (ja) * 1982-10-08 1984-04-16 Green Cross Corp:The 超音波診断造影剤
JPS59112936A (ja) * 1982-12-21 1984-06-29 Green Cross Corp:The ペルフルオロエ−テル化合物及びその製造法
US4640833A (en) * 1983-02-28 1987-02-03 Adamantech, Inc. Use of perfluorobromoalkyl ethers as X-ray contrast agents
SE8505048L (sv) * 1985-10-25 1987-04-26 Nutritional Int Res Inst Nutritionsemulsion med syretransporterande egenskaper
US4865836A (en) * 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4895876A (en) * 1987-03-20 1990-01-23 Air Products And Chemicals, Inc. Concentrated stable fluorochemical aqueous emulsions containing triglycerides

Also Published As

Publication number Publication date
ES2056932T3 (es) 1994-10-16
NO883456L (no) 1989-02-06
EP0307087B1 (en) 1994-06-08
CA1316820C (en) 1993-04-27
DE3850012D1 (de) 1994-07-14
NO179162B (no) 1996-05-13
US4987154A (en) 1991-01-22
EP0307087A1 (en) 1989-03-15
ATE106722T1 (de) 1994-06-15
ZA885796B (en) 1990-04-25
NO179162C (no) 1996-08-21
IE882416L (en) 1989-02-05
DE3850012T2 (de) 1995-01-19
IE64245B1 (en) 1995-07-26

Similar Documents

Publication Publication Date Title
NO883456D0 (no) Bioforenlige, stabile og konsentrerte fluorcarbonemulsjoner for kontrastoekning og oxygentransport invortes i dyr.
DE60121027T2 (de) Lösung zur evaluierung und konservierung
Au et al. Luminal acidification by the perfused rat cauda epididymidis
ES431706A1 (es) Un procedimiento de preparacion de emulsiones de compuestosfluorados en agua o en soluciones salinas.
KR890011585A (ko) 경피식 피임약제제형
Phillips et al. Water and electrolyte transport during maintenance of isotonicity in human jejunum and ileum
DE68906153D1 (de) Humanes relaxinpraeparat.
ES2037136T3 (es) Procedimiento para la preparacion de una solucion con elevada actividad volumetrica de una proteina con actividad de activador de plasminogeno de tejidos (t-pa).
ES2064801T3 (es) Emusion estable apropiada para la administracion farmaceutica, procedimiento para su obtencion, y emulsion para la aplicacion como medicamento.
Stromberg et al. Effects of oncotic gradients and enzymes on negative pressures in implanted capsules
JPS56106594A (en) Stabilizing method of plasminogen
Cumming et al. Bone-marrow blood flow and cardiac output in the rabbit
Hiernickel An improved method for in vitro perfusion of human skin
DK0630651T3 (da) Halvfast farmaceutisk middel og fremgangsmåde til fremstilling heraf
Swanson et al. Excretion of phenytoin into semen of rabbits and man. Comparison with plasma levels.
EP0458930B1 (de) STABILISIERUNG VON GLYKOSYLIERTEM t-PA
ATE76574T1 (de) Osmotisches system zur verabreichung von verduennten loesungen.
Parsons et al. Some properties of a preparation of rat colon perfused in vitro through the vascular bed
ATE243527T1 (de) Arzneistoff zur erleichterung der durch immunsuppressiva verursachten nebenwirkungen
Linask et al. Perfusion preservation of hearts for 6 to 9 days at room temperature
Wood et al. Calciuria in total parenteral nutrition: effects of amino acids and glucose in rats
ES2122962T3 (es) Derivados de alquileno-dioxibenceno opticamente activos y su uso en terapia.
Mercier et al. Effects of parathyroid hormone and urinary phosphate on collecting duct hydrogen secretion
Good et al. Ammonia absorption by the thick ascending limb of Henle’s loop
Michel One hundred years of Starling's hypothesis

Legal Events

Date Code Title Description
MK1K Patent expired